MedPath

Paroxetine

Generic Name
Paroxetine
Brand Names
Paxil, Pexeva
Drug Type
Small Molecule
Chemical Formula
C19H20FNO3
CAS Number
61869-08-7
Unique Ingredient Identifier
41VRH5220H
Background

Paroxetine is a selective serotonin reuptake inhibitor (SSRI) drug commonly known as Paxil. It has a variety of uses, including the treatment of anxiety disorders, major depression, posttraumatic stress disorder, and symptoms of menopause, among others. It was approved by the FDA in the early 1990s and marketed by SmithKline Beecham. A unique feature of this drug is that it is highly potent and selective in its inhibition of serotonin reuptake and has little effect on other neurotransmitters. Because of its potent inhibition of serotonin reuptake, paroxetine is more likely to cause withdrawal effects upon cessation. Paroxetine is well tolerated in most patients with a similar adverse effect profile to other members of its drug class. The controlled release formulation was designed to decrease the likelihood of nausea that is sometimes associated with paroxetine.

Indication

Paroxetine is indicated for the management of depression, obsessive-compulsive disorder, panic disorder, social anxiety disorder, generalized anxiety disorder, posttraumatic stress disorder. One form of paroxetine, commercially known as Brisdelle, is used to manage mild to moderate vasomotor symptoms of menopause. Off-label, paroxetine may be used for the treatment of premature ejaculation or irritable bowel syndrome (IBS).

Associated Conditions
Generalized Anxiety Disorder, Irritable Bowel Syndrome (IBS), Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Post Traumatic Stress Disorder (PTSD), Premature Ejaculation, Premenstrual Dysphoric Disorder (PMDD), Social Anxiety Disorder (SAD), Vasomotor Symptoms Associated With Menopause

Treatment of Patients With Major Depressive Disorder With MK0869 (0869-066)(COMPLETED)

Phase 3
Completed
Conditions
Major Depressive Disorder
First Posted Date
2002-05-03
Last Posted Date
2017-04-26
Lead Sponsor
Merck Sharp & Dohme LLC
Target Recruit Count
900
Registration Number
NCT00034983

Evaluation of Clonazepam and Paroxetine for Panic Disorder With Depression

Phase 4
Completed
Conditions
Panic Disorder
First Posted Date
2002-03-01
Last Posted Date
2008-03-04
Lead Sponsor
National Institute of Mental Health (NIMH)
Target Recruit Count
60
Registration Number
NCT00031317
Locations
🇺🇸

National Institute of Mental Health (NIMH), Bethesda, Maryland, United States

Treatment Effects on Platelet Calcium in Hypertensive and Depressed Patients

Phase 4
Completed
Conditions
Depression
Hypertension
First Posted Date
2001-07-05
Last Posted Date
2009-01-21
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00018759
Locations
🇺🇸

Edward Hines Jr. Hospital, Hines, Illinois, United States

Biological Aspects of Depression and Antidepressant Drugs

Not Applicable
Completed
Conditions
Depression
First Posted Date
2001-07-05
Last Posted Date
2009-01-21
Lead Sponsor
US Department of Veterans Affairs
Registration Number
NCT00018733
Locations
🇺🇸

South Texas Veterans Health Care System, San Antonio, Texas, United States

Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)

Not Applicable
Completed
Conditions
Bipolar Disorder
First Posted Date
2001-03-15
Last Posted Date
2007-05-04
Lead Sponsor
National Institute of Mental Health (NIMH)
Target Recruit Count
5000
Registration Number
NCT00012558
Locations
🇺🇸

Case Western Reserve University, Cleveland, Ohio, United States

🇺🇸

University of Pennsylvania Medical Center, Philadelphia, Pennsylvania, United States

🇺🇸

University of Pittsburgh, Pittsburgh, Pennsylvania, United States

and more 8 locations

Treatment of Panic Disorder: Long Term Strategies

Phase 3
Completed
Conditions
Panic Disorder
Agoraphobia
First Posted Date
1999-11-03
Last Posted Date
2014-03-18
Lead Sponsor
New York State Psychiatric Institute
Target Recruit Count
379
Registration Number
NCT00000368
Locations
🇺🇸

University of Pittsburgh, Department of Psychiatry, Panic, Anxiety and Traumatic Grief Program, Pittsburgh, Pennsylvania, United States

🇺🇸

Hillside Hospital Phobia Clinic, New York, New York, United States

🇺🇸

Yale University, Department of Psychiatry, Anxiety Disorders Research Clinic, New Haven, Connecticut, United States

and more 1 locations
© Copyright 2025. All Rights Reserved by MedPath